IMMP

Immutep

• PR Newswire·2d ago

  Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

• Reuters·4d ago

  Immutep director Peter Andrew Meyers files initial beneficial ownership statement

• Reuters·04/01 10:21

  Immutep files initial beneficial ownership statement for Chief Medical Officer Stephan Winckels

• Reuters·04/01 10:17

  Immutep files Form 3 as director Frederic Triebel reports 11.4 million shares owned

• Reuters·04/01 10:14

  Immutep files Form 3 as director Russell John Howard reports beneficial ownership

• Reuters·04/01 10:11

  Immutep files Form 3 as Chief Development Officer Christian Mueller reports beneficial ownership

• NASDAQ·03/20 14:13

  Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal

• TipRanks·03/20 10:29

  Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress

• Reuters·03/19 19:07

  Rosen Law Firm probes potential securities class action over Immutep disclosures

• TipRanks·03/19 12:28

  Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

• Benzinga·03/19 12:04

  Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases

• Reuters·03/19 12:00

  IMMUTEP REPORTS PROGRESS FROM PHASE I STUDY OF LAG-3 AGONIST FOR AUTOIMMUNE DISEASES

• Reuters·03/19 01:19

  Immutep completes Phase I single ascending dose trial of IMP761 up to 14 mg/kg

• Dow Jones·03/16 22:21

  *Immutep Downgraded to Speculative Hold from Speculative Buy by Bell Potter

• Dow Jones·03/16 22:20

  *Immutep Price Target Cut 89% to A$0.07/Share by Bell Potter